Welcome to our dedicated page for Cartesian SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cartesian Therapeutics, Inc. (NASDAQ: RNAC) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Cartesian describes itself as a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, with lead CAR-T programs Descartes-08 and Descartes-15. Its SEC filings offer detailed information on clinical development, financial position, governance and risk factors that complement the company’s press releases.
Investors researching RNAC can use this page to review current and historical Forms 10-K and 10-Q for audited and interim financial statements, discussion of operations, and disclosures about the Descartes-08 and Descartes-15 programs. Form 8-K filings provide timely updates on material events, such as clinical data announcements, trial initiations or pauses, changes in development priorities, financial results releases, board appointments and executive transitions, amendments to bylaws, and updates to the company’s code of business conduct and ethics.
Cartesian’s filings also document equity awards and inducement grants, board and committee roles, and other compensation arrangements, which can be relevant for understanding governance and incentive structures. Where applicable, proxy materials describe director elections and governance policies, and registration statements outline the terms of any registered offerings.
Stock Titan enhances these RNAC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify important disclosures related to Descartes-08’s Phase 3 AURORA trial in myasthenia gravis, expansion into myositis and pediatric indications, and the status of Descartes-15. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, and 10-Ks appear promptly, while Form 4 insider transaction reports can be reviewed to see equity transactions by directors and officers as disclosed to the SEC.
By combining original SEC documents with AI-generated explanations, this page helps users interpret Cartesian Therapeutics’ regulatory reporting, understand how clinical and strategic developments are reflected in official filings, and follow the evolution of RNAC as a clinical-stage biotechnology issuer.
Cartesian Therapeutics (RNAC) reported a Form 4 for its Chief Accounting Officer, June Ann Seymour, documenting an equity award. On 10/27/2025, Seymour received an employee stock option50,000 shares at an exercise price of $8.85 per share, expiring on 10/27/2035.
The option vests as to 25% on 10/27/2026, with the remaining underlying shares vesting in three equal annual installments so that all shares are fully vested on 10/27/2029. The filing lists ownership of the derivative security as Direct (D) with 50,000 derivative securities beneficially owned following the reported transaction.
Cartesian Therapeutics, Inc. (RNAC) filed a Form 3 initial statement of beneficial ownership for officer June Ann Seymour, who serves as Chief Accounting Officer. The filing states that no securities are beneficially owned.
The date of the event requiring the statement is 10/27/2025. The form was filed by one reporting person and signed by /s/ Matthew Bartholomae as attorney-in-fact pursuant to an Exhibit 24 power of attorney.
Cartesian Therapeutics (RNAC) eliminated its Chief Scientific Officer role and provided a termination without cause notice to Christopher Jewell, Ph.D., effective November 14, 2025. The company and Dr. Jewell subsequently entered into a separation agreement on October 20, 2025.
Under the agreement, Dr. Jewell released claims through November 14, 2025 in exchange for severance benefits defined in his March 26, 2024 employment agreement, including 12 months of salary and eligibility for a pro‑rated bonus. The separation agreement will be filed with the company’s Annual Report on Form 10‑K for the year ending December 31, 2025.
Cartesian Therapeutics, Inc. reported that its Board of Directors appointed June Seymour as Chief Accounting Officer, effective October 27, 2025. She brings over 20 years of financial leadership in life sciences, including senior finance roles at DNAnexus, Neogene Therapeutics, Autolus and earlier experience at Ernst & Young.
Under her employment agreement, Ms. Seymour will receive an annual base salary of $385,000 and will be eligible for an annual performance bonus targeted at 35% of base salary, prorated for 2025. If her employment is terminated without cause or she resigns for good reason, she may receive six months of salary continuation, a pro-rated bonus and up to six months of COBRA premium payments, subject to customary release and restrictive covenants.
Ms. Seymour will also receive a $80,000 sign-on bonus and an option to purchase 50,000 shares of common stock at the closing price on the October 27, 2025 grant date. The option vests over four years, with 25% after 12 months and the remainder in three equal annual installments. She is subject to non-compete and non-solicitation covenants, and has signed the company’s standard executive indemnification agreement. The company’s Chief Financial Officer, Blaine Davis, remains the principal financial and principal accounting officer.